A carregar...
Escape from ALL-CARTaz: Leukemia immunoediting in the age of chimeric antigen receptors
Chimeric antigen receptor (CAR) T-cell therapy has been transformative for the treatment of B-cell malignancies, with CD19- and CD22-directed CARs being prime examples. However, immunoediting and ensuing antigen loss remain the major obstacle to curative therapy in up to 25% of patients. For example...
Na minha lista:
| Publicado no: | Cancer J |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6617517/ https://ncbi.nlm.nih.gov/pubmed/31135529 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000381 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|